FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067040316> ?p ?o ?g. }

• W2067040316 endingPage "19771" @default.
• W2067040316 startingPage "19771" @default.
• W2067040316 abstract "In a recent clinical trial (ACTG 5257), no difference in viral failure (VF) of a first-line cART containing atazanavir/r (ATV/r) or darunavir/r (DRV/r) was found [1]. For the endpoint of discontinuation due to intolerance, the regimen with DRV/r was superior to that of ATV/r (49% of the stops of ATV/r were attributed to jaundice or hyperbilirubinemia). These and other intolerances to ATV/r remain a concern for clinicians.Participants in the ICONA Foundation Study who started cART with 2NRTI+ ATV/r or DRV/r while ART-naïve were included. Several endpoints were evaluated: confirmed VF>200 copies/mL after six months of therapy, discontinuation of DRV/r or ATV/r for any reasons or because of intolerance/toxicity (as reported by the treating physician) and the combined endpoint of VF or stop. Survival analysis with Kaplan-Meier curves and Cox regression model stratified by clinical site was used. Patients' follow-up accrued from cART initiation to the date of the event or to the date of last available visit/viral load.894 patients starting 2NRTI+ATV/r and 686 2NRTI+DRV/r when ART-naïve on average in 2011 (IQR: 2010-2012) were studied. Most common NRTIs used were FTC/TDF (84%) and ABC/3TC (12%). Median age was 40 years, 22% females, 44% heterosexuals. Patients starting ATV/r were more likely to be hepatitis B/C infected (2% and 14% vs 1% and 9%, p=0.001), they started one year earlier (2011 vs 2012, p=0.001), were more likely to be enrolled in sites located in the north of Italy (63% vs 54%, p=0.04), started cART less promptly after HIV diagnosis (5 vs 2 months, p=0.02) and less likely to have started TDF/FTC (83% vs 85%, p=0.02). By two years of cART, 9.8% (95% CI 7.6-12.0) of those starting ATV/r experienced discontinuation due to intolerance/toxicity vs 6.5% in DRV/r group (95% CI 4.2-8.8, p=0.04). After controlling for several potential confounders (age, gender, nation of birth, mode of HIV transmission, hepatitis co-infection status, AIDS diagnosis, nucleoside pair started, baseline CD4 count and viral load and year of starting cART) the relative hazard (RH) for ATV/r vs DRV/r was 2.01 (95% CI 1.23, 3.28, p=0.005). There were no statistical differences detected for any of the other outcomes.Although unmeasured confounding cannot be ruled out, our results seem to be consistent with those of the ACTG 5257. When all cause discontinuations were considered, or the composite endpoint of treatment failure, there was no difference between ATV/r- and DRV/r-based regimens." @default.
• W2067040316 created "2016-06-24" @default.
• W2067040316 creator A5001547379 @default.
• W2067040316 creator A5012360574 @default.
• W2067040316 creator A5015091157 @default.
• W2067040316 creator A5022289412 @default.
• W2067040316 creator A5047438814 @default.
• W2067040316 creator A5049035721 @default.
• W2067040316 creator A5052366087 @default.
• W2067040316 creator A5057599036 @default.
• W2067040316 creator A5064631193 @default.
• W2067040316 creator A5082122622 @default.
• W2067040316 creator A5085992339 @default.
• W2067040316 date "2014-11-01" @default.
• W2067040316 modified "2023-10-17" @default.
• W2067040316 title "An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy" @default.
• W2067040316 doi "https://doi.org/10.7448/ias.17.4.19771" @default.
• W2067040316 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4225250" @default.
• W2067040316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25397515" @default.
• W2067040316 hasPublicationYear "2014" @default.
• W2067040316 type Work @default.
• W2067040316 sameAs 2067040316 @default.
• W2067040316 citedByCount "2" @default.
• W2067040316 countsByYear W20670403162014 @default.
• W2067040316 countsByYear W20670403162015 @default.
• W2067040316 crossrefType "journal-article" @default.
• W2067040316 hasAuthorship W2067040316A5001547379 @default.
• W2067040316 hasAuthorship W2067040316A5012360574 @default.
• W2067040316 hasAuthorship W2067040316A5015091157 @default.
• W2067040316 hasAuthorship W2067040316A5022289412 @default.
• W2067040316 hasAuthorship W2067040316A5047438814 @default.
• W2067040316 hasAuthorship W2067040316A5049035721 @default.
• W2067040316 hasAuthorship W2067040316A5052366087 @default.
• W2067040316 hasAuthorship W2067040316A5057599036 @default.
• W2067040316 hasAuthorship W2067040316A5064631193 @default.
• W2067040316 hasAuthorship W2067040316A5082122622 @default.
• W2067040316 hasAuthorship W2067040316A5085992339 @default.
• W2067040316 hasBestOaLocation W20670403161 @default.
• W2067040316 hasConcept C126322002 @default.
• W2067040316 hasConcept C127413603 @default.
• W2067040316 hasConcept C142462285 @default.
• W2067040316 hasConcept C203014093 @default.
• W2067040316 hasConcept C203092338 @default.
• W2067040316 hasConcept C2777275308 @default.
• W2067040316 hasConcept C2778414717 @default.
• W2067040316 hasConcept C2778715236 @default.
• W2067040316 hasConcept C2779182219 @default.
• W2067040316 hasConcept C2781413609 @default.
• W2067040316 hasConcept C2993143319 @default.
• W2067040316 hasConcept C3013748606 @default.
• W2067040316 hasConcept C50382708 @default.
• W2067040316 hasConcept C535046627 @default.
• W2067040316 hasConcept C71924100 @default.
• W2067040316 hasConcept C78519656 @default.
• W2067040316 hasConceptScore W2067040316C126322002 @default.
• W2067040316 hasConceptScore W2067040316C127413603 @default.
• W2067040316 hasConceptScore W2067040316C142462285 @default.
• W2067040316 hasConceptScore W2067040316C203014093 @default.
• W2067040316 hasConceptScore W2067040316C203092338 @default.
• W2067040316 hasConceptScore W2067040316C2777275308 @default.
• W2067040316 hasConceptScore W2067040316C2778414717 @default.
• W2067040316 hasConceptScore W2067040316C2778715236 @default.
• W2067040316 hasConceptScore W2067040316C2779182219 @default.
• W2067040316 hasConceptScore W2067040316C2781413609 @default.
• W2067040316 hasConceptScore W2067040316C2993143319 @default.
• W2067040316 hasConceptScore W2067040316C3013748606 @default.
• W2067040316 hasConceptScore W2067040316C50382708 @default.
• W2067040316 hasConceptScore W2067040316C535046627 @default.
• W2067040316 hasConceptScore W2067040316C71924100 @default.
• W2067040316 hasConceptScore W2067040316C78519656 @default.
• W2067040316 hasLocation W20670403161 @default.
• W2067040316 hasLocation W20670403162 @default.
• W2067040316 hasLocation W20670403163 @default.
• W2067040316 hasLocation W20670403164 @default.
• W2067040316 hasLocation W20670403165 @default.
• W2067040316 hasOpenAccess W2067040316 @default.
• W2067040316 hasPrimaryLocation W20670403161 @default.
• W2067040316 hasRelatedWork W1976863253 @default.
• W2067040316 hasRelatedWork W2024677219 @default.
• W2067040316 hasRelatedWork W2050892293 @default.
• W2067040316 hasRelatedWork W2084137080 @default.
• W2067040316 hasRelatedWork W2092811583 @default.
• W2067040316 hasRelatedWork W2162937465 @default.
• W2067040316 hasRelatedWork W2270630361 @default.
• W2067040316 hasRelatedWork W2509806891 @default.
• W2067040316 hasRelatedWork W2939164830 @default.
• W2067040316 hasRelatedWork W3186451085 @default.
• W2067040316 hasVolume "17" @default.
• W2067040316 isParatext "false" @default.
• W2067040316 isRetracted "false" @default.
• W2067040316 magId "2067040316" @default.
• W2067040316 workType "article" @default.